# ATTORNEY DOCKET NO. 9250.22

PATENT # 1/29-20-91

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Goudsmit, et al.

Serial No.:

09/463,352

Group Art Unit: 1655

Filed:

January 21, 2000

For:

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND

PROBES IN THE AMPLIFICATION AND DETECTION OF ALL

**SUBTYPES OF HIV-1** 

June 18, 2001

RECEIVED

SEP 2 0 2001

Commissioner for Patents Washington, DC 20231

**TECH CENTER 1600/2900** 

# REQUEST FOR CORRECTED FILING RECEIPT

Sir:

TRADEN

In reviewing the Filing Receipt (copy attached) for the above referenced application, Applicant notes that the invention title appears incorrectly as NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS PROBES IN AMPLIFICATION AND DETECTION OF ALL SUBTYES OF HIV-1. The invention title should read NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS **AND** PROBES IN THE AMPLIFICATION AND DETECTION OF ALL SUBTYPES OF HIV-1.

Applicant further respectfully requests that a corrected filing receipt be issued.

Respectfully submitted,

Kenneth D. Sibley

Registration No. 31,665

## **USPTO Customer No. 20792**


Myers Bigel Sibley & Sajovec Post Office Box 37428 Raleigh, North Carolina 27627 Telephone (919) 854-1400 Facsimile (919) 854-1401

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on June 18, 2001.

Vickie Diane Prior

Date of Signature: June 18, 2001





#### UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT	D CLAIMS
09/463,352	01/21/2000	1646	840	T/97300 US	MAR 2 8 2000	1
WILLIAM M BLACKST	ONE				BY:	

AKZO NOBEL 1300 PICCARD DRIVE **SUITE #206** ROCKVILLE, MD 20850-4373

Date Mailed: 03/24/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER. FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

JAAP GOUDSMIT, AMSTERDAM, NETHERLANDS; PIETER OUDSHOORN, ST. MICHIELSGESTEL, NETHERLANDS; SUZANNE JURRIAANS, MONNICKENDAM, NETHERLANDS; VLADIMIR VLADIMIROVICH LUKASHOV, DIEMEU, NETHERLANDS;

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/EP98/04945 08/05/1998

#### Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 97202455.8 08/08/1997

If Required, Foreign Filing License Granted 03/24/2000

## Title

NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS PROBES IN AMPLIFICATION DETECTION OF ALL SUBTYES OF HIV-1

# **Preliminary Class**

435



Data entry by : BARRETO, NGA

Team: OIPE

Date: 03/24/2000

## 

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

SEP 2 0 2001 TECH CENTER 1600/2900

## GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

